Modern WisdomHealth Hacks Big Pharma Doesn’t Want You To Know - Biohacking Roundtable
At a glance
WHAT IT’S REALLY ABOUT
Biohacking roundtable debates peptides, GLP-1s, stem cells, testosterone, and longevity basics
- This roundtable surveys popular biohacking interventions—peptides, GLP-1 microdosing, stem cells, testosterone therapy, sauna/cold, breathwork, and environmental controls—through a mix of clinical anecdotes and selective research references.
- A central tension is medical innovation versus regulation: they argue compounding and “right-to-try” frameworks enable safer access than forcing consumers into unregulated gray markets.
- GLP-1 drugs are treated as a permanent shift in medicine with benefits (weight loss, possibly inflammation) but major second-order risks including sarcopenia, under-fueling exercise, mood/anhedonia, and sex-drive changes, especially when high trial-based dosages are applied broadly.
- They push for reframing testosterone and other anabolics as legitimate replacement/healthspan tools when clinically indicated, criticizing outdated dogma and emphasizing individualized assessment beyond one lab cutoff.
- The episode also spotlights ‘non-pharma’ priorities—strength training, VO2 max, brisk walking speed, sleep/HRV via resonance breathing, and environmental exposures (mold, air quality, plastics, EMFs)—as foundational longevity levers.
IDEAS WORTH REMEMBERING
5 ideasPeptides are ‘condiments,’ not the main course.
They frame peptides as situational tools (immune support while traveling, injury repair, occasional GH-axis cycles), not daily foundations, and repeatedly stress that diet, training, sleep, and lifestyle come first.
GLP-1s may be powerful beyond weight loss, but dosing and context are being misapplied.
They describe microdosing (e.g., ~0.25) for “quieting food noise,” travel convenience, and potential inflammation reduction; they also flag that the strongest data largely comes from sick/morbidly obese populations at higher doses, which may not translate to the general public.
GLP-1 ‘muscle loss’ is partly measurement error and partly behavior-driven.
The group argues muscle loss often stems from low food intake and reduced training capacity rather than a direct GLP-1 mechanism, and that DEXA can misclassify “lean mass” changes by mixing in reductions in intramuscular/intrahepatic fat.
Suppressing appetite may also suppress desire and reward—especially in some women.
They note emerging observations that GLP-1s can dampen dopamine-mediated reward pathways (food, shopping, sex), with claims of reduced female libido and mood/pleasure changes; they connect this to addiction research interest (alcohol/drugs) and raise societal implications (“GLP to GDP”).
Testosterone replacement is framed as deficiency treatment with meaningful healthspan upside—yet culturally moralized.
They attribute testosterone’s demonization to historical medical dogma (a small early prostate-cancer-linked study, later debunked) plus sports/“shortcut” stigma; they emphasize distinctions between replacement vs enhancement and discuss receptor variability (e.g., androgen receptor CAG repeats) and fertility preservation options (HCG, banking sperm).
WORDS WORTH SAVING
5 quotesI tell everyone the answer's not at the bottom of a peptide bottle. Like, diet, lifestyle, nutrition, uh, living by the principles first.
— Brigham Buhler
We are at the precipice of trading obesity for sarcopenia ... right now
— Dr. Gabrielle Lyon
Osteoporosis is a pediatric disease with geriatric outcomes.
— Dr. Gabrielle Lyon
No one. And so is this, you know, increase in longevity just a distraction from the end result, which is that we will all die?
— Dr. Gabrielle Lyon
We did a retrospective analysis of 16 million patients that were on BPC-157. Out of that, we found three adverse events. Three adverse events.
— Brigham Buhler
High quality AI-generated summary created from speaker-labeled transcript.
